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Background and Objectives. The study aims to assess the usefulness of age-independent criteria CURSI and temperature adjusted
CURSI (CURASI) compared to CURB-65 in predicting community-acquired pneumonia (CAP) mortality. The criteria, CRSI and
CRASI, were adapted for use in primary care and compared to CRB-65. Methods. A retrospective analysis of a prospectively
identified cohort of community-acquired pneumonia inpatients was conducted. Outcomes were (1) mortality and (2) mortality
and/or ICU admission within six weeks. Results. 95 patients (median age = 61 years) were included. All three criteria had similar
sensitivity in predicting mortality alone, with CURB-65 having slightly higher specificity. When predicting mortality and/or
intensive care admission, CURSI/CURASI showed higher sensitivity and slightly lower specificity. CRSI and CRASI had higher
sensitivity and lower specificity when compared with CRB-65 for predicting both primary and secondary outcomes. Results for
both analyses had P values >0.05. Conclusions. In a cohort of younger patients CURSI and adjusted CURSI perform at least as well
as CURB-65, with a similar trend for CRSI and adjusted CRSI compared to CRB-65. Further studies are needed in different age
groups and in primary and secondary care settings.
1. Introduction
Community-acquired pneumonia (CAP) is a leading cause
of hospital admission, patient death, and a significant burden
on health service resources in the UK [1]. Mortality rates
are highest in patients considered to have severe pneumonia
[2–5]. Ultimate mortality rates for patients requiring ICU
admission have been reported at over 40% [6, 7]. Early
recognition of severely ill patients is important to predict
those with the worst prognosis, and a dependable method of
assessing pneumonia severity may refine initial management
of these patients by helping clinicians decide whether close
monitoring and aggressive treatment are required. Correctly
identifying severe community-acquired pneumonia cases
will also reduce the inappropriate use of intravenous antibi-
otics, thereby reducing the risk of antibiotic-associated colitis,
which is an important issue for health service utilisation,
mortality, and morbidity [8]. The CURB-65 severity index,
recommended by the British Thoracic Society [9], compares
similarly with other severity scores [10] and is a readily
applied tool that can be used to guide site of care and degree of
medical intervention. Recent comprehensive reviews [10, 11]
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have drawn attention to the limitations of current established
community-acquired pneumonia severity assessment crite-
ria.
CURB-65 criteria are based on; confusion; urea > 7
mmol/L; respiratory rate ≥ 30/min; systolic (<90mmHg) or
diastolic (≤60mmHg) blood pressure; and age ≥65 years,
scoring one mark each [5]. Patients with scores of 3 or
more are classed as having severe pneumonia.While younger
and older patients alike have been shown to mount similar
immunoresponses to pneumonia infection [12], concerns
over the use of age-dependent scoring systems have been
raised given the variability of presentation between different
age groups [13]. The potential for misleadingly low scores in
patients younger than 65 years has been declared [14, 15].The
inclusion of chronological age in severity assessments may
also lead to false positive results amongst some older patients
while, conversely, systolic hypertension with increasing age
may lead to false negatives in older patients. It has also been
suggested that low diastolic blood pressure (≤60mmHg) is
not predictive of mortality in older patients [16, 17] and may
be due to reductions in mean diastolic blood pressure with
physiological ageing. Diastolic blood pressure criteria may
therefore not have the same implication for older patients
as for younger patients, further complicating its use as
part of CURB-65 severity scoring. Cardiovascular shock in
community-acquired pneumonia has previously been iden-
tified as an independent prognostic factor for mortality [18].
We have previously reported that using the shock index (SI),
the ratio of heart rate to systolic blood pressure, in place of
age may have future potential use based on retrospectively
collected audit data [19] as part of a scoring criteria combined
with confusion, urea, and respiratory rate (CURSI/CURASI).
CURSI and CURASI criteria showed comparable usefulness
to CURB-65 in predicting mortality in a cohort of older
patients with a median age of 76 years (𝑛 = 190) [20].
The CURB-65 derivation study [5] also presented the
CRB-65 criteria which is adapted for use in primary care.
The exclusion of urea as a marker of severity negates the
need for any biochemical testing, and the patient’s score
is calculated solely on clinical measurements which can be
recorded by a general practitioner before deciding onwhether
to admit a patient to hospital or maintain care within the
community. Such decisions have important implications for
both the patient, the healthcare professionals looking after
them, and the resources available to both. CRB-65 has shown
similar effectiveness to CURB-65 in the hospital setting,
and the measurement of urea may not offer any further
predictive ability to CURB-65 [4, 21–24]. A recent meta-
analysis of CRB-65 [25] reports howerver that it overpredicts
the probability of mortality in the community setting and
should be used with caution.
The aim of this study was to assess the usefulness of
CURSI and CURASI compared to CURB-65 in predicting
community-acquired pneumonia (CAP) severity in a rela-
tively young patient cohort. CRB-65 was also compared to
CRSI and CRASI scores in a separate analysis.
2. Methods
Unselected adults admitted to a respiratory team in a large
acute general hospital with community-acquired pneumonia
were included in the study. CAP was defined as the presence
of new shadowing on admission chest X-ray and clinical fea-
tures consistent with pneumonia (e.g., cough, sputum expec-
toration, shortness of breath, and pleuritic chest pain with or
without fever). Only patients in whom CAP was the main
reason for admission were included. Any patients in whom
there was an expected terminal event or who developed
hospital-acquired pneumonia were excluded from the study.
Patients were followed up in the respiratorymedical clinic six
weeks following admission. Datawere collected prospectively
over a 14-month period (April 1999–June 2000), as has
been previously reported [3]. Hospital guidelines based on
a previous British Thoracic Society study [21] were in use
throughout this time period and used in guiding patient care.
Analysis was conducted retrospectively, using mortality at 6
weeks and mortality and/or ICU admission at 6 weeks as
outcomes. Data was collected for 96 patients in total, with one
patient being excluded from the CURB-65/CURSI/CURASI
analysis (𝑛 = 95) and a different patient being excluded from
the CRB-65/CRSI/CRASI analysis (𝑛 = 95) due to missing
values.
In this study, CURSI scores were derived from confusion;
urea > 7mmol/L; respiratory rate ≥ 30/min; and a shock
index ratio > 1.0, scoring one mark each. CURSI was also
applied with an adjusted shock index score (CURASI) where
10 points were deducted from the heart rate for every 1.0∘C
increase in the patient’s temperature above 37.0∘C [20]. This
adjustment was to account for the physiological increase
in heart rate with rising temperature. CURSI and CURASI
scores of 2 or more were classed as severe pneumonia. Except
for the exclusion of urea as a marker of severity, CRB-65
and CRSI/CRASI criteria were calculated using the same
variables and cutoff points. CRB-65 scores of 3 or more and
CRSI/CRASI scores of 2 or more were classed as severe.
Five patients had one data variable missing from CURB-
65, CURSI, and CURASI severity scoring, with one patient
being excluded from the study due to a borderline score
and allocation to the non-severe group which may have
been switched to the severe group depending on the missing
urea value. However, due to the results of the remain-
ing four patients’ recorded data (non-severe patients all
scored 0 points, 𝑛 = 3; severe patient scored 2 points
[CURSI/CURASI] and 3 points [CURB-65], 𝑛 = 1) these
patients were confirmed in the groups they were originally
allocated, irrespective of any absent values. One patient was
excluded from CRB-65, CRSI, and CRASI analyses due to a
missing value for confusion status, which gave the patient a
borderline non-severe CRB-65 score of 2 and CRSI/CRASI
scores of 1. The addition of a positive confusion value may
have resulted in an allocation to the severe group, and the
patient was therefore excluded. The adjustment of shock
index to calculate the CURASI and CRASI scores resulted in
different values for the shock index in forty-seven patients.
One patient was reclassified from the severe to non-severe
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Confusion
Urea > 7 mmol/L
Respiratory rate ≥ 30/min
Confusion
Urea > 7 mmol/L
Respiratory rate ≥ 30/min
(Adjusted) shock index > 1
Severe: CURSI/ASI ≥ 2
n = 31
Non-severe: CURSI/ASI ≤ 1
n = 64
Died, n = 7
Died and/or ITU, n = 9
Alive without ITU, n = 15
Died, n = 7
Died and/or ITU, n = 8
Alive without ITU, n = 13
Died, n = 1
Died and/or ITU, n = 2
Alive without ITU, n = 61
Died, n = 1
Died and/or ITU, n = 3
Alive without ITU, n = 63
SBP < 90 mmHg or DBP ≤ 60 mmHg
Aged ≥ 65 years
Severe: CURB-65 ≥ 3
n = 28
Non-severe: CURB-65 ≤ 2
n = 67
Figure 1: Severity and outcomes according to CURSI, CURASI, and
CURB-65 groups, 𝑛 = 95.
group in the CRSI/CRASI analysis. None were reclassified in
the CURSI/CURASI analysis.
The sensitivities, specificities, and positive and negative
predictive values were calculated for each of the criteria.
Comparisons between the sensitivity and specificity results
for bothCURSI/CURASI andCURB-65 and for CRSI/CRASI
and CRB-65 were performed using the Wilcoxon Signed-
Rank Test. Statistical significance was taken as a 𝑃 value of
≤0.05. SPSS 18.0 (IBM, NY, USA) statistical package was used
to analyse the data.
The study data was collected as part of an internal
audit cycle, and so local ethical committee approval was not
required.
3. Results
95 patients (54 males and 41 females) were eligible to be
included in the current report. No patient with missing data
for parameters required for severity scoring was included
in the analysis, unless their remaining recorded values con-
firmed their allocation to either the non-severe or severe
group. Patients were aged 17–96 years (median age 61 years,
Confusion
Respiratory rate ≥ 30/min
(Adjusted) shock index > 1
Confusion
Respiratory rate ≥ 30/min
SBP < 90 mmHg or DBP ≤ 60 mmHg
Aged ≥ 65 years
Severe: CURB-65 ≥ 3
n = 11
Non-severe: CURB-65 ≤ 2
n = 84
Died, n = 3
Died and/or ITU, n = 4
Alive without ITU, n = 4
Died, n = 5
Died and/or ITU, n = 8
Alive without ITU, n = 71
Non-severe: CRSI (CRASI) ≤ 1
n = 75 (76)
Died, n = 6 (6)
Died and/or ITU, n = 7 (7)
Alive without ITU, n = 7 (6)
Died, n = 2 (2)
Died and/or ITU, n = 5 (5)
Alive without ITU, n = 68 (69)
n = 20 (19)
Severe: ≥ 2CRSI ∗(CRASI)
Figure 2: Severity and outcomes according to CRSI, CRASI, and
CRB-65 groups, 𝑛 = 95. ∗CRASI figures are detailed in ().
mean age 58.8 years). Eight patients died (aged 55–80 years)
during the study. Ten patients were admitted to ICU, six
of whom died. Three of the four ICU survivors were aged
less than 65 years. One of these patients was excluded from
the CURSI/CURASI/CURB-65 analysis due to missing urea
values but was included in the CRSI/CRASI/CRB-65 analysis.
Therefore, eleven patients either died orwere admitted to ITU
in the CURSI/CURASI/CURB-65 analysis, while there were
twelve such patients in the CRSI/CRASI/CRB-65 analysis.
Figure 1 presents the severity groups to which patients
were allocated according to CURSI/CURASI/CURB-65 and
their outcomes. CURSI and CURASI performed similarly,
identifying 31 (32%) of 95 patients as having severe pneu-
monia. 7 of whom died. CURSI and CURASI classed 9 of
the patients who either died and/or were admitted to ITU
as severe. CURB-65 classed 28 (29%) of the cases as having
severe pneumonia. 7 of these patients died. CURB-65 classed
8 patients who either died and/or were admitted to ITU as
severe.
Figure 2 presents the severity groups to which patients
were allocated according to CRSI/CRASI/CRB-65 and their
outcomes. CRSI classed 20 (21%) of 95 patients as severe.
CRASI classed 19 (20%) patients as severe. CRSI and CRASI
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Table 1: Sample characteristics for selected variables included in
CURB-65, CURSI, and CURASI criteria.
Variables median (range)/number (%) mean (±sd)
Age (all) 61 (17–96) 58.8 (±18.752)
Age group
<65 years 51 (53.6%)
≥ 65 years 44 (46.3%)
Sex
Men 54 (56.8%)
Women 41 (43.1%)
Confusion 27 (28.4%)
Urea 6.65 (1–30.9) 7.9 (±5.111)
Resp. rate 24 (10–40) 24.2 (±6.455)
Blood pressure
Systolic 130 (75–208) 130.8 (±26.995)
Diastolic 74 (40–113) 72.9 (±14.409)
Pulse rate 100 (56–170) 101.86 (±19.38)
Temperature 37.9 (33.4–40) 37.78 (±1.1756)
Data presented as median (range)/mean (±sd) for continuous data or
number (%) for categorical data.
classed 6 of the 8 patients who died as severe and classed 7 of
the patients who either died and/or were admitted to ITU as
severe. CRB-65 classed 11 (12%) patients as severe, of whom 3
died and a fourth patient was admitted to ITU.
Table 1 presents the cohort sample characteristics, includ-
ing for age, gender, confusion, urea levels, respiratory
rate, blood pressure, heart rate, and temperature. Median
(ranges)/mean (±sd) values and numbers (percentages) are
detailed.
Table 2 presents sensitivity, specificity, and positive and
negative predictive values of CURB-65, CURSI, and CURASI
calculated for mortality and for mortality and/or ICU admis-
sion. All three severity indices compared similarly for sen-
sitivity (87.5%, CI 46.7–99.3, and 𝑃 = 0.18) for mortality
alone, with CURB-65 having 3.4% higher specificity (75.8%,
CI 65.3–84.1) than CURSI/CURASI (72.4%, CI 61.6–81.1, and
𝑃 = 1.00). When predicting for mortality and/or intensive
care admission, the results suggest that CURSI/CURASI
showed 9.1% higher sensitivity (81.8%, CI 47.7–96.8) com-
pared to CURB-65 (72.7%, CI 39.3–92.6, and 𝑃 = 0.31) with
a slightly lower (2.4%) specificity than CURB-65 (𝑃 = 0.31).
Results did not reach a significance level of 𝑃 < 0.05, as will
be discussed in the next section.
Table 3 presents sensitivity, specificity, and positive and
negative predictive values for CRB-65, CRSI, and CRASI with
regard to mortality and to mortality and/or ICU admission.
The results suggest the higher sensitivity of CRSI (75%, CI
35.6–95.5, and 𝑃 = 0.15) and CRASI (75%, CI 35.6–95.5, and
𝑃 = 0.25) when compared with CRB-65 (50%, CI 17.4–82.5)
for predicting mortality, with a higher specificity of CRB-65
(91.9%, CI 83.6–96.4) than CRSI (83.9%, CI 74.1–90.6, and
𝑃 = 0.15) and CRASI (85.0%, CI 75.4–91.5, and 𝑃 = 0.15).
In predicting mortality and/or intensive care admission the
results followed the same trend by suggesting the higher
sensitivity of CRSI (58.3%, CI 28.6–83.5, and 𝑃 = 0.18)
and CRASI (58.3%, CI 28.6–83.5, and 𝑃 = 0.41) to CRB-65
(33.3%, CI 11.3–64.6) and a higher specificity with CRB-65
(91.6%, CI 82.8–96.2) when compared with CRSI (84.3%, CI
74.3–91.1, and 𝑃 = 0.08) and CRASI (85.5%, CI 75.7–91.9, and
𝑃 = 0.15).
4. Discussion
The study has some limitations, the foremost of which is
the small sample size. Statistically the comparisons between
the criteria did not reach significance (𝑃 ≤ 0.05), which
may be attributable to this sample size. However without a
statistical difference between the groups, the indication is
that both CURSI/CURASI and CRSI perform at least as well
as CURB-65 or CRB-65, respectively. The analyses suggest a
trend of CURSI and CURASI both showing higher sensitivity
with only a slight reduction in specificity, and similar results
were seen when comparing CRSI and CRASI to CRB-
65. These results reflect previous findings in the literature
with regard to the higher sensitivity of CURSI/CURASI
compared to CURB-65 criteria [20]. A limitation of the CRB-
65/CRSI/CRASI analysis was that this was an inpatient cohort
rather than outpatients or those seen in the community by
general practitioners and therefore may have reduced gener-
alisability to this setting. In primary care, outcomes such as
hospital admission, clinical deterioration, or reconsultation
may be of as much interest to the general practitioner as
mortality or ICU admission.
Replacing increasing age and blood pressure with the
shock index may have greater predictive value of mortality
and/or admission to ICU. This would be encouraging in the
clinical setting as identifying patients who have the greatest
need for specialist treatment is of most importance. The
unadjusted shock index calculation can be done readily at
the bedside simply by sight recognition of whether the heart
rate has exceeded the systolic blood pressure. If it has, then
the ratio will be greater than 1 and a point can be added to
the patient’s score. This ease of calculation may also prove
beneficial where the age of the patient is unknown due to
patient confusion or in the emergency setting.
The data was collected thirteen years ago with the patient
cohort managed using hospital guidelines of that time. We
used this data for its hypothesis generating ability as it has
the thought provoking value that patients were managed
and triaged in the absence of CURB-65 criteria because,
unlike cohorts in recent studies, this study’s cohort predates
the derivation and widespread use of CURB-65. Therefore,
the results are not confounded by CURB-65, neither, firstly,
playing a role in the severity assessment of individual patients
nor, secondly, guiding the treatment decisions made during
patient care that may have influenced ICU admission or
mortality. This allows for the unbiased comparison of each
of the scoring criteria against each other, to see what the
predicted outcomes would be if any of the three criteria had
actually been applied at the time of admission.
It is of note that, with a median age of 61 years, the
findings are in a younger cohort than the original CURB-65
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Table 2: Sensitivity, specificity, positive and negative predictive values, and corresponding 95% confidence intervals for CURB-65, CURSI,
and CURASI criteria for six-week mortality and for mortality and/or ICU admission in 95 community-acquired pneumonia cases.
All (𝑛 = 95) Mortality Mortality and/or ICU admission
CURB-65 CURSI CURASI CURB-65 CURSI CURASI
Sensitivity 87.5%(46.7–99.3)
87.5%
(46.7–99.3)
87.5%
(46.7–99.3)
72.7%
(39.3–92.6)
81.8%
(47.7–96.8)
81.8%
(47.7–96.8)
Specificity 75.8%(65.3–84.1)
72.4%
(61.6–81.1)
72.4%
(61.6–81.1)
76.2%
(65.4–84.5)
73.8%
(62.9–82.5)
73.8%
(62.9–82.5)
Positive predictive value 25.0%(11.4–45.2)
22.6%
(10.3–41.5)
22.6%
(10.3–41.5)
28.6%
(13.9–48.8)
29.0%
(14.9–48.2)
29.0%
(14.9–48.2)
Negative predictive value 98.5%(90.9–99.9)
98.4%
(90.5–99.9)
98.4%
(90.5–99.9)
95.5%
(86.6–98.8)
96.9%
(88.2–99.4)
96.9%
(88.2–99.4)
Table 3: Sensitivity, specificity, positive and negative predictive value, and corresponding 95% confidence intervals for CRB-65, CRSI, and
CRASI criteria for six-week mortality and for mortality and/or ICU admission in 95 community-acquired pneumonia cases.
All (𝑛 = 95) Mortality Mortality and/or ICU admission
CRB-65 CRSI CRASI CRB-65 CRSI CRASI
Sensitivity 50.0%(17.4–82.5)
75.0%
(35.6–95.5)
75.0%
(35.6–95.5)
33.3%
(11.3–64.6)
58.3%
(28.6–83.5)
58.3%
(28.6–83.5)
Specificity 91.9%(83.6–96.4)
83.9%
(74.1–90.6)
85.0%
(75.4–91.5)
91.6%
(82.8–96.2)
84.3%
(74.3–91.1)
85.5%
(75.7–91.9)
Positive predictive value 36.4%(12.4–68.4)
30%
(12.8–54.3)
31.6%
(13.5–56.5)
36.4%
(12.4–68.4)
35.0%
(16.3–59.0)
36.8%
(17.2–61.3)
Negative predictive value 95.2%(87.6–98.5)
97.3%
(89.8–99.5)
97.4%
(89.9–99.5)
90.5%
(81.6–95.5)
93.3%
(84.5–97.5)
93.4%
(84.7–97.5)
derivation study (median age 69) [5].While death is generally
a rare occurrence in previously healthy younger adults, most
studies have validated CURB-65 based on the risk of death
in older cohorts, so overall risk to younger patients remains
relatively unclear. One study did show that CURB-65 had
a low sensitivity (54%) for predicting need for mechanical
ventilation and/or inotropic support in patients less than 50
years of age [22]. The current study adds to this result by
suggesting that CURB-65 has lower sensitivity than shock
index criteria for predicting the need for intensive treatment
in a relatively young cohort of patients. We did not adjust for
the effect of drugs that patients were already taking which
may have had an impact on the heart rate and blood pressure,
for example, beta-blockers. However, the study purpose was
to examine the usefulness of simple clinical parameters to
help clinical decision-making (e.g., urea level does not need
to take into consideration kidney function in CURB-65).
The application of age-independent criteria, such as
CURSI andCURASI,may offer promising alternative severity
indices, by removing the possibility of false negatives on the
basis of younger age. The inclusion of the shock index may
also address concerns over CURB-65 predictions in older
patients whose increasing prevalence of systolic hypertension
may interfere with severity scoring. Equally, in the absence
of urea measurements, calculating the shock index could
provide a useful and practical predictive tool in both primary
care or emergency settings and help guide the need for
admission and acceleration of treatment. The CRSI and
CRASI also offer criteria of interest in this regard.
5. Conclusions
Given the high mortality still associated with community-
acquired pneumonia, there are continued purpose and
benefit to find new means of assessing patients. Our
hypothesis generating study has findings suggesting that
CURSI/CURASI and CRSI/CRASI show potential in severity
assessment. Further prospective studies with larger cohorts
and wider age ranges in different populations and settings are
required.
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